(Q37982204)

26 August 2017

title

Metabolic syndrome: definition and therapeutic implications (English)

1 reference

26 August 2017

1 reference

Hari Prasad

1

1 reference

26 August 2017

Debra A Ryan

series ordinal

2

1 reference

26 August 2017

Ma Florence Celzo

series ordinal

3

1 reference

26 August 2017

Dwight Stapleton

series ordinal

4

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 January 2012

1 reference

26 August 2017

published in

Postgraduate Medicine

1 reference

26 August 2017

volume

124

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

21-30

1 reference

Childhood obesity predicts adult metabolic syndrome: the Fels Longitudinal Study

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Metabolic obesity: the paradox between visceral and subcutaneous fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

The escalating pandemics of obesity and sedentary lifestyle. A call to action for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Development of fatness, fitness, and lifestyle from adolescence to the age of 36 years: determinants of the metabolic syndrome in young adults: the amsterdam growth and health longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Prevalence of the metabolic syndrome among patients receiving clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Clinical application of C-reactive protein for cardiovascular disease detection and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Metabolic syndrome and risk of cardiovascular disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Components of the "metabolic syndrome" and incidence of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Usual dietary fat intake and insulin concentrations in healthy women twins.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Saturated fat intake and insulin resistance in men with coronary artery disease. The Stanford Coronary Risk Intervention Project Investigators and Staff.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Dietary fat intake and the risk of coronary heart disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

A dose-response relation between aerobic exercise and visceral fat reduction: systematic review of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Exercise-induced reduction in obesity and insulin resistance in women: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Aerobic exercise is necessary to improve glucose utilization with moderate weight loss in women

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Aerobic exercise, lipids and lipoproteins in overweight and obese adults: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Effects of aerobic exercise on lipids and lipoproteins in adults with type 2 diabetes: a meta-analysis of randomized-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Effects of exercise, diet and weight loss on high blood pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma cholesterol level

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Simvastatin with or without ezetimibe in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Athe

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Metabolic syndrome: treatment of hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Bariatric surgery: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Metabolic aspects of bariatric surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Metabolic syndrome: a solution in search of a problem

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Long-Term Epidemiologic Prediction of Coronary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

Effect of Aerobic Exercise Training on Serum Levels of High-Density Lipoprotein Cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.01.2514

21 January 2018

Identifiers

DOI

10.3810/PGM.2012.01.2514

1 reference

26 August 2017

1 reference